MedStar Montgomery Medical Center, formerly known as Montgomery General Hospital, is a large hospital in Olney, Maryland. The hospital is a member of MedStar Health..
BACKGROUND:Wide variability of how clinicians diagnose Lemierre Syndrome (LS) exists within the literature leading to "Lemierre-like" conditions. Some clinicians use Fusobacterium bacteremia as key defining feature, while some use internal jugular septic thrombophlebitis. The source of infection varies as well between oropharyngeal and skin and soft tissue infection. METHODS:This literature-based observational analysis utilized existing case reports to find common clinical patterns in diagnosis to construct a clinical decision tree framework. 149 LS cases from PubMed and Google Scholar over a 13-year period between January 2012 and December 2024 were obtained. A novel clinical framework was constructed based on a testing cohort of 111 cases and applied to a separate cohort of 38 cases. RESULTS:LS has been rising in recent years, with 88 cases within the past five years. Among all included cases, the most common findings included bacteremia (123/149;82.6%), internal jugular venous septic thrombophlebitis (123/149;82.6%), pulmonary septic emboli/cavitary lesion (99/149;66.4%). Fusobacteria species comprised 39.6% (59/149) of positive blood cultures. 74.5% of 149 cases were oropharyngeal infections while 25.5% were skin and soft tissue infections. Based on these patterns, we organized a clinical framework consisting of "Presumed Lemierre," "LS Type I," "Type II," "Type III," and "Type IV/Variant". Compared to the historical definition, our proposed modified definition of LS effectively assigned reported LS cases from the literature into a subtype based on clinical features. CONCLUSIONS:Our study is hypothesis-generating and offered a modified definition of LS and incorporated clinical observations into a unifying framework to address the existing ambiguity and variation with this entity.
Effective clinical and public health decision-making during a pandemic depends on reliable and interoperable clinical diagnostic test results. To ensure trustworthy outcomes, we need widely available calibration standards harmonized to a shared scale. We present a “playbook” for an interlaboratory harmonization study that calibrates any available standards against a limited-availability standard issued by a global authority like the World Health Organization (WHO).
Ovarian cancer stem cells (CSCs) can seed recurrent drug-resistant disease. Likewise, non-CSCs can acquire CSC phenotypic properties. How this process is orchestrated is of interest to inform how it might be prevented. We tested the hypothesis that ovarian CSC and/or drug-resistant tumor cells confer stem-like properties via extracellular vesicles (EVs). We focused our investigation on how EVs might mediate EZH2 signaling to promote a phenotypic change in drug-sensitive, non-CSCs. To accomplish this, we utilized paired PARP inhibitor-sensitive and - resistant ovarian cancer (OvCa) cell lines, EZH2 knockdown lines, and patient-derived organoids (PDOs) originating from recurrent high-grade serous OvCa. Small EVs isolated from drug-sensitive, CSC and/or drug-resistant enriched cultures, PARP inhibitor (olaparib) resistant lines, or drug-treated (olaparib or carboplatin) lines were cultured with treatment naïve or sensitive lines for defined time points. The impact of small EV exposure was determined by assessing cell number, metabolic activity, viability, sphere and colony-forming capacity, ALDH activity, DNA damage, and changes in associated signaling pathways. We found that EVs from CSC or drug-resistant enriched cell fractions communicate CSC-like phenotypes to the more sensitive tumor cells via EZH2 canonical and non-canonical signaling pathways, promoting stemness. We conclude that EV-mediated activation of EZH2 signaling represents a targetable mechanism contributing to stemness-associated drug resistance in OvCa. Graphical abstract:
In this case report, we present a term baby with prenatal CF diagnosis with a neonatal course complicated by left sided congenital diaphragmatic hernia which was not visualized during prenatal screenings. During pregnancy, a prenatal ultrasound at 30 weeks revealed a right-sided pleural effusion, which resolved by 31 weeks. Maternal testing identified carrier status for biotinidase deficiency and CF, and paternal testing also showed CF carrier status. Amniocentesis confirmed CF with two CFTR mutations (G551D and 1461ins4). Although off-label ETI therapy was considered, however through shared-decision making, it was not initiated. At 37 weeks, ultrasound showed a left-sided pleural effusion, heart shift, and ascites indicating hydrops. The baby was delivered via induced vaginal delivery at 37+1 weeks gestation due to concern for impending hydrops fetalis. Immediately after birth, the baby was intubated and a chest tube was placed due to severe respiratory distress in the setting of left sided pleural effusion and concern for tension pneumothorax. Initial days of his neonatal course were complicated with multiorgan failure including echo revealing pericardial effusions with an ejection fraction of 39% upon admission, AST and ALT of 4,177 U/L and 1,182 U/L, respectively, and grade 2 intraventricular hemorrhages.The baby required a multidisciplinary approach, including a cooling protocol that was discontinued after 2 hours due to abnormal coagulation parameters, and hydrocortisone for cardiac support. He remained intubated for 11 days and was successfully transitioned to CPAP on day 11 of life. Within the following weeks, the baby showed significant improvement with resolution of multiorgan failure. He was started on ivacaftor therapy for CF on day 39. He was eventually discharged on day 56 and has been doing well since, experiencing weight gain and no respiratory issues. He continues on ivacaftor. This case underscores the complexities of managing neonates with CF and concurrent congenital anomalies, highlighting the importance of early prenatal diagnosis and a multidisciplinary approach. It also emphasizes the need for further research to explore the interplay between CF and associated congenital conditions, as well as the uncommon neonatal presentations of CF. Additionally, rigorous studies are needed to assess the risk/benefit ratio of prenatal ETI use to improve management and outcomes.